Log in to your Inderes Free account to see all free content on this page.

Vitrolife

141.30 SEK

+1.51 %

Less than 1K followers

VITR

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

+1.51 %

-1.26 %

+2.91 %

-10.23 %

-34.28 %

-36.69 %

-30.19 %

-32.52 %

+2,202.43 %

Vitrolife is an international group that provides medical devices and genetic services. The company develops and manufactures services and products for personalized genetic information as well as medical devices in the field of fertility. Vitrolife supports customers in their operations to improve patient outcomes from fertility treatments. Vitrolife's products and services are available globally. The company is headquartered in Gothenburg, Sweden.

Market cap

19.14B SEK

Turnover

28.82M SEK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

3.2.

2026

Annual report '25

23.4.

2026

Interim report Q1'26

6.5.

2026

General meeting '26

All

Webcasts

Press releases

3rd party

ShowingAll content types

Press release10/29/2025, 8:00 AM

Nomination committee of Vitrolife AB (publ) for the Annual General Meeting 2026

Vitrolife, Audiocast, Q3'25

Webcast10/23/2025, 8:00 AM

Vitrolife, Audiocast, Q3'25

Regulatory press release10/23/2025, 6:00 AM

Vitrolife AB (publ): Interim report Q3, 2025: Strong growth in Americas

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Press release10/9/2025, 8:00 AM

Vitrolife AB (publ): Invitation to Vitrolife Group's presentation of the Q3 2025 interim report

Press release7/22/2025, 6:29 AM

Redeye: Vitrolife - The tough get going

Vitrolife, Audiocast, Q2'25

Webcast7/17/2025, 8:00 AM

Vitrolife, Audiocast, Q2'25

Regulatory press release7/17/2025, 6:00 AM

Vitrolife AB (publ): Interim report Q2, 2025: Strong performance across Consumables

Press release7/3/2025, 12:00 PM

Vitrolife AB (publ): Invitation to Vitrolife Group's presentation of the Q2 2025 interim report

Press release7/1/2025, 9:00 AM

Vitrolife AB (publ): Vitrolife Group completes refinancing facility backed by leading Nordic Banks

Press release5/8/2025, 1:49 PM

Vitrolife AB (publ) becomes lead investor in AutoIVF

Regulatory press release4/30/2025, 7:08 AM

Report from Annual General Meeting of Vitrolife AB (publ)

Regulatory press release4/29/2025, 2:56 PM

Report from Annual General Meeting of Vitrolife AB (publ)

Press release4/28/2025, 8:03 AM

Redeye: Vitrolife Update - Good efforts in a challenging period

Regulatory press release4/24/2025, 6:00 AM

Vitrolife AB (publ): Interim report Q1, 2025: Strong performance in EMEA

Regulatory press release4/10/2025, 10:00 AM

Vitrolife AB (publ): The Vitrolife Group appoints Pär Ihrskog as the new Chief Financial Officer

Press release4/10/2025, 8:00 AM

Vitrolife AB (publ): Conference call interim report

Regulatory press release3/31/2025, 9:30 AM

Vitrolife AB (publ): The Vitrolife Group introduces changes to the executive management team and strengthens focus on innovation

Regulatory press release3/27/2025, 8:00 AM

Vitrolife AB (publ): Vitrolife Group Annual and Sustainability Report 2024

Regulatory press release3/25/2025, 5:30 PM

Notice to attend the Annual General Meeting of Vitrolife AB (publ)

Press release3/24/2025, 9:25 AM

Redeye: Vitrolife - Enters 2025 fighting

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.